bioMérieux SA

bioMérieux SA is a French multinational biotechnology company founded in 1963 and headquartered in Marcy-l'Étoile, near Lyon, France. As a world leader in the field of in vitro diagnostics for over 60 years, bioMérieux pioneers diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's mission is 'WE HELP MAKE THE WORLD A HEALTHIER PLACE' through innovative diagnostic technologies. bioMérieux operates through four key business segments: Hospital and Laboratory Solutions, Point of Care Testing, Food Safety & Quality, and Pharmaceutical Quality Control. The company's comprehensive portfolio includes the BIOFIRE molecular diagnostics platform for multiplex testing, VITEK microbiology systems for identification and susceptibility testing, VIDAS immunoassay diagnostics, and GENE-UP PCR testing solutions. With 14,754 employees worldwide, bioMérieux serves more than 160 countries through 39 subsidiaries and an extensive distributor network. The company achieved revenues of €3.98 billion in 2024, representing 10.3% organic growth, with 93% of sales occurring outside France. bioMérieux specializes in clinical and industrial microbiology, multiplex molecular diagnostics, and syndromic testing, maintaining a strong niche position in the fragmented in vitro diagnostic market. The company focuses on critical areas including antimicrobial stewardship, sepsis management, respiratory infections, COVID-19 testing, and next-generation sequencing. Recent strategic initiatives include the acquisition of Day Zero Diagnostics to enhance genomic capabilities and collaboration with Moderna on individualized cancer therapies. Listed on Euronext Paris (BIM), bioMérieux continues to drive innovation in infectious disease diagnostics, serving clinical laboratories, hospitals, and industrial customers globally while maintaining its founding family's commitment to public health advancement.